Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-0623 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GDC-0623 | DRUG | Repeating oral dose |
Inclusion Criteria: * Histologically or cytologically documented, locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable * Evaluable disease or disease measurable per RECIST * Life expectancy \>= 12 weeks * Adequate hema...
GDC-0623 is an investigational small molecule being studied for the treatment of solid cancers. It is intended for patients with locally advanced or metastatic solid tumors. The drug is currently in clinical development and has not been approved by regulatory authorities.
The molecular target of GDC-0623 has not been disclosed in available information. The drug is a small molecule being evaluated for its safety, tolerability, and pharmacokinetics in patients with solid tumors. Its mechanism of action is not publicly detailed.
GDC-0623 is being developed by Roche Holding AG, a multinational healthcare company. Roche is listed on the OTC market under the ticker symbol RHHBY. The drug is currently in Phase 1 clinical development.
GDC-0623 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for safety, tolerability, and pharmacokinetics in patients with solid tumors.
GDC-0623 has one completed clinical trial, NCT01106599, which evaluated the safety, tolerability, and pharmacokinetics of the drug in patients with locally advanced or metastatic solid tumors. The trial was conducted in the United States and enrolled 61 participants.